1.85  -0.01 (-0.52%)		05-16 16:00
Open: 1.83 High: 1.87 Volume: 2,306		Pre. Close: 1.8597 Low: 1.83 Market Cap: 19(M)

Short term
Mid term
Targets	6-month :	2.56	1-year :	3
Resists	First :	2.2	Second :	2.56
Pivot price	1.91
Supports	First :	1.52	Second :	1.1
MAs	MA(5) :	1.85	MA(20) :	1.91
	MA(100) :	2.09	MA(250) :	2.83
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	68.4	D(3) :	68.7
RSI	RSI(14): 44.5
52-week	High :	13.92	Low :	1.1

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ANL ] has closed above bottom band by 28.5%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.87 - 1.88	1.88 - 1.89
Low:	1.81 - 1.82	1.82 - 1.83
Close:	1.83 - 1.85	1.85 - 1.87

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

Mon, 25 Mar 2024
Atomic Layer Deposition (ALD) Used to Create Ultrablack Coating Perfect for Viewing the Cosmos - Securities.io

Tue, 03 Oct 2023
Adlai Nortye Ltd. Announces Closing of Initial Public Offering - GlobeNewswire

Fri, 29 Sep 2023
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering - GlobeNewswire

Sat, 17 May 2025

Sat, 17 May 2025

Sat, 17 May 2025

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	31 (M)
Held by Insiders	5.361e+007 (%)
Held by Institutions	5.6 (%)
Shares Short	6 (K)
Shares Short P.Month	0 (K)

EPS	-5.192e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	220.8 %
Return on Equity (ttm)	-32.9 %
Qtrly Rev. Growth	1.94e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0.13
EBITDA (p.s.)	-1.8
Qtrly Earnings Growth	-1.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-52 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	13.65
Price to Cash Flow	0

Dividend	0
Forward Dividend	2980
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.